These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34515355)

  • 1. Patient-reported outcomes and quality of life in dominant dystrophic epidermolysis bullosa: A global cross-sectional survey.
    Fulchand S; Harris N; Li S; Barriga M; Gorell E; De Souza M; Murrell D; Marinkovich MP; Krishna Yenamandra V; Tang JY
    Pediatr Dermatol; 2021 Sep; 38(5):1198-1201. PubMed ID: 34515355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: A global cross-sectional survey.
    Eng VA; Solis DC; Gorell ES; Choi S; Nazaroff J; Li S; de Souza MP; Murrell DF; Marinkovich MP; Tang JY
    J Am Acad Dermatol; 2021 Nov; 85(5):1161-1167. PubMed ID: 32199895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex.
    So JY; Fulchand S; Wong CY; Li S; Nazaroff J; Gorell ES; de Souza MP; Murrell DF; Teng JM; Chiou AS; Tang JY
    Orphanet J Rare Dis; 2022 Jul; 17(1):270. PubMed ID: 35841105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dominant dystrophic epidermolysis bullosa is associated with glycolytically active GATA3+ T helper 2 cells which may contribute to pruritus in lesional skin.
    Aala WJF; Hou PC; Hong YK; Lin YC; Lee YR; Tu WT; Papanikolaou M; Benzian-Olsson N; Onoufriadis A; I Chen Harn H; Hwang DY; Cheng SM; Lu K; Chen PC; McGrath JA; Hsu CK
    Br J Dermatol; 2024 Jul; 191(2):252-260. PubMed ID: 38477474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ophthalmologic Approach in Epidermolysis Bullosa: A Cross-Sectional Study With Phenotype-Genotype Correlations.
    Mellado F; Fuentes I; Palisson F; I Vergara J; Kantor A
    Cornea; 2018 Apr; 37(4):442-447. PubMed ID: 29384803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Participatory co-design of patient-reported outcome indicators and N-of-1 evaluation of a dressing glove for Epidermolysis bullosa.
    Graham T; Sooriah S; Box R; Gage H; Williams P; Clemett V; Grocott P
    J Wound Care; 2020 Dec; 29(12):751-762. PubMed ID: 33320744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa.
    Tang JY; Marinkovich MP; Lucas E; Gorell E; Chiou A; Lu Y; Gillon J; Patel D; Rudin D
    Orphanet J Rare Dis; 2021 Apr; 16(1):175. PubMed ID: 33849616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hindi translation and validation of quality of life score in Indian patients with epidermolysis bullosa; and its correlation with the clinical severity assessment scores: A cross-sectional study.
    Bishnoi A; Manjunath S; Kishore K; De D; Handa S; Murrell DF; Mahajan R
    Indian J Dermatol Venereol Leprol; 2022; 88(2):177-183. PubMed ID: 34491666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical spectrum of dystrophic epidermolysis bullosa.
    Horn HM; Tidman MJ
    Br J Dermatol; 2002 Feb; 146(2):267-74. PubMed ID: 11903238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study.
    Bornert O; Hogervorst M; Nauroy P; Bischof J; Swildens J; Athanasiou I; Tufa SF; Keene DR; Kiritsi D; Hainzl S; Murauer EM; Marinkovich MP; Platenburg G; Hausser I; Wally V; Ritsema T; Koller U; Haisma EM; Nyström A
    J Invest Dermatol; 2021 Apr; 141(4):883-893.e6. PubMed ID: 32946877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective short-term study to evaluate methodologies for the assessment of disease extent, impact, and wound evolution in patients with dystrophic epidermolysis bullosa.
    Paller AS; Pope E; Rudin D; Malyala A; Ramsdell D; Johnson R; Landy H; Murrell DF;
    Orphanet J Rare Dis; 2022 Aug; 17(1):314. PubMed ID: 35964087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compound Heterozygosity of Dominant and Recessive COL7A Alleles in a Severely Affected Patient with a Family History of Dystrophic Epidermolysis Bullosa: Clinical Findings, Genetic Testing, and Treatment Implications.
    Watson KD; Schoch JJ; Beek GJ; Hand JL
    Pediatr Dermatol; 2017 Mar; 34(2):166-171. PubMed ID: 28297147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the Timing of Milestone Clinical Events in Patients With Epidermolysis Bullosa From North America.
    Feinstein JA; Jambal P; Peoples K; Lucky AW; Khuu P; Tang JY; Lara-Corrales I; Pope E; Wiss K; Hook KP; Levin LE; Morel KD; Paller AS; McCuaig CC; Powell J; Eichenfield LF; Price H; Levy ML; Schachner LA; Browning JC; Bayliss S; Jahnke M; Shwayder T; Glick SA; Bruckner AL
    JAMA Dermatol; 2019 Feb; 155(2):196-203. PubMed ID: 30586139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved erythema and decreased blister formation in dominant dystrophic epidermolysis bullosa following treatment with pulsed dye laser.
    Garza-Mayers AC; Su KA; Wiss K
    Pediatr Dermatol; 2022 Nov; 39(6):1005-1006. PubMed ID: 36063122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermolysis Bullosa (EB) Acquisita in an Adult Patient with Previously Unrecognized Mild Dystrophic EB and Biallelic COL7A1 Mutations.
    Guerra L; Condorelli AG; Fortugno P; Calabresi V; Pedicelli C; Di Zenzo G; Castiglia D
    Acta Derm Venereol; 2018 Apr; 98(4):411-415. PubMed ID: 29182795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermolysis Bullosa: Pediatric Perspectives.
    Hon KL; Chu S; Leung AKC
    Curr Pediatr Rev; 2022; 18(3):182-190. PubMed ID: 34036913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of mobility, activities and pain in different subtypes of epidermolysis bullosa.
    Fine JD; Johnson LB; Weiner M; Suchindran C
    Clin Exp Dermatol; 2004 Mar; 29(2):122-7. PubMed ID: 14987264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inside out: regenerative medicine for recessive dystrophic epidermolysis bullosa.
    Vanden Oever M; Twaroski K; Osborn MJ; Wagner JE; Tolar J
    Pediatr Res; 2018 Jan; 83(1-2):318-324. PubMed ID: 29593249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rare case of recessive dystrophic epidermolysis bullosa with aplasia cutis and pyloric stenosis.
    Sawka E; Dhossche J; Funk T
    JAAD Case Rep; 2021 Jan; 7():134-136. PubMed ID: 33426253
    [No Abstract]   [Full Text] [Related]  

  • 20. Rat model for dominant dystrophic epidermolysis bullosa: glycine substitution reduces collagen VII stability and shows gene-dosage effect.
    Nyström A; Buttgereit J; Bader M; Shmidt T; Ozcelik C; Hausser I; Bruckner-Tuderman L; Kern JS
    PLoS One; 2013; 8(5):e64243. PubMed ID: 23717576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.